According to a commentary, bortezomib-based VR-CAP therapy represents a substantial advance for the treatment of mantle cell lymphoma. However, for its widespread adoption, especially in elderly patients, the administration method (particularly of bortezomib) needs to be carefully considered, and the routine use of maintenance rituximab seems sensible. It adds that whether VR-CAP or the combination of bortezomib and bendamustine-based regimens will be the optimal approach has yet to be established, but if R-CHOP is being considered, then these long-term survival data strongly support the use of VR-CAP as an alternative.